Page last updated: 2024-11-12

1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11731903
CHEMBL ID3185063
SCHEMBL ID372352
MeSH IDM0493570

Synonyms (45)

Synonym
NCGC00248983-01
dtxcid4027943
NCGC00258614-01
cas-174899-82-2
tox21_201061
dtxsid4047967 ,
E0599
1-ethyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide
174899-82-2
AKOS015904108
emim tfsi
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide
emim bti
SCHEMBL372352
1-ethyl-3-methylimidazolium bis(trifluoromethanesulfonyl)amide
1-ethyl-3-methyl imidazolium bis(trifluoromethanesulfonyl)imide
1-ethyl-3-methylimidazolium bis((trifluoromethyl)sulfonyl)imide
AKOS025286124
CHEMBL3185063
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide, >=98% (hplc)
mfcd03788927
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide, >=97.0% (nmr)
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide, 99% [emiim]
1-ethyl-3-methylimidazolium bis(pentafluoromethanesulfonyl)imide
[emim][ntf2]
3-ethyl-1-methyl-1h-imidazol-3-ium bis((trifluoromethyl)sulfonyl)amide
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide, >=99%, h2o <=500 ppm
1-ethyl-3-methyl-1h-imidazol-3-ium bis(trifluoromethylsulfonyl)amide
bis(trifluoromethylsulfonyl)azanide;1-ethyl-3-methylimidazol-3-ium
emiim
BCP17053
FT-0702748
CS-W011726
BS-15590
C80082
1-(3-carboxypyridyl-2)-2-phenyl-4-methylpiperazine
SY041803
1-ethyl-3-methyl-3-imidazolium bis[(trifluoromethyl)sulfonyl]amide
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide, 99per cent [emiim]
A881650
1-ethyl-3-methylimidazolium bis[(trifluoromethyl)sulfonyl]imide
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide [emiim]
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide (nmr)
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide,
1-ethyl-3-methylimidazoliumbis((trifluoromethyl)sulfonyl)imide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.52830.006038.004119,952.5996AID1159521
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.41370.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.92620.000229.305416,493.5996AID743080
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency44.00450.001019.414170.9645AID743191
activating transcription factor 6Homo sapiens (human)Potency24.74560.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (43.48)29.6817
2010's12 (52.17)24.3611
2020's1 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.94 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index41.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]